Big Pharma Wants to Pocket the Profits from a COVID Treatment You Already Paid For. Institute for New Economic Thinking Perspectives

Matthew James Jackson; Fred Ledley

Big Pharma Wants to Pocket the Profits from a COVID Treatment You Already Paid For. Institute for New Economic Thinking Perspectives

Matthew James Jackson
, Fred Ledley

Natural and Applied Sciences

Research output: Other contribution

Abstract

What is a fair price for Gilead’s remdesivir as a treatment for COVID-19? This has been a burning question in the media and policy circles from the moment Gilead received Emergency Use Authorization (EUA) for the drug as a therapy for COVID-19.

Original language	English
Volume	July (3rd Quarter/Summer)
State	Published - 2020

Publication series

Name	Institute for New Economic Thinking (INET)

Cite this

@misc{58bf5449e7444974aad2560fab6dc2d3,

title = "Big Pharma Wants to Pocket the Profits from a COVID Treatment You Already Paid For. Institute for New Economic Thinking Perspectives",

abstract = "What is a fair price for Gilead{\textquoteright}s remdesivir as a treatment for COVID-19? This has been a burning question in the media and policy circles from the moment Gilead received Emergency Use Authorization (EUA) for the drug as a therapy for COVID-19.",

author = "Jackson, \{Matthew James\} and Fred Ledley",

year = "2020",

language = "English",

volume = "July (3rd Quarter/Summer)",

series = "Institute for New Economic Thinking (INET)",

type = "Other",

}

TY - GEN

T1 - Big Pharma Wants to Pocket the Profits from a COVID Treatment You Already Paid For. Institute for New Economic Thinking Perspectives

AU - Jackson, Matthew James

AU - Ledley, Fred

PY - 2020

Y1 - 2020

N2 - What is a fair price for Gilead’s remdesivir as a treatment for COVID-19? This has been a burning question in the media and policy circles from the moment Gilead received Emergency Use Authorization (EUA) for the drug as a therapy for COVID-19.

AB - What is a fair price for Gilead’s remdesivir as a treatment for COVID-19? This has been a burning question in the media and policy circles from the moment Gilead received Emergency Use Authorization (EUA) for the drug as a therapy for COVID-19.

UR - https://www.ineteconomics.org/perspectives/blog/big-pharma-covid-profits

M3 - Other contribution

VL - July (3rd Quarter/Summer)

T3 - Institute for New Economic Thinking (INET)

ER -

Big Pharma Wants to Pocket the Profits from a COVID Treatment You Already Paid For. Institute for New Economic Thinking Perspectives

Abstract

Publication series

Other files and links

Fingerprint

Cite this